Plitidepsin
DCTPepD ID DCTPepD0072
Active Ingredients Plitidepsin
Description A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.
Synonyms APLD; Aplidin; Aplidine; DDB; Dehydrodemnin B; N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A; Plitidepsin
Disease Various forms of cancer
Classification
Peptide and derivative Cyclic Marine origin
Structure Information
Molecular Formula C57H87N7O15
Molecular Weight 1110.3
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
InChI InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
InChI_Key UUSZLLQJYRSZIS-LXNNNBEUSA-N
SMILES CC[C@@H]([C@H]1NC([C@H]([C@H](OC([C@@H](N(C([C@@H]2CCCN2C([C@@H](NC([C@H](C([C@@H](OC(C[C@@H]1O)=O)C(C)C)=O)C)=O)CC(C)C)=O)=O)C)CC3=CC=C(C=C3)OC)=O)C)NC([C@H](N(C([C@@H]4CCCN4C(C(C)=O)=O)=O)C)CC(C)C)=O)=O)C
External Codes
PubChem CID 9812534
DrugBank Accession Number DB04977
NCI Thesaurus Code C1689
UNII Y76ID234HW GSRS
CAS 137219-37-5
Drug approval
Drug indication
Intended for the treatment of various forms of cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT03070964 | A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma | Lymphoma | Phase 2 | Treatment |
| NCT02100657 | Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | Phase 1 | Other |
| NCT01102426 | Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | Phase 3 | Treatment |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial | Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma | Phase 2 | Treatment |
| NCT00788099 | Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas | Advanced Solid Tumors; Lymphomas | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
